Meng L - Search Results

1

Discovery of Pyrido[2,3-d]pyrimidin-7-one Derivatives as Highly Potent and Efficacious Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Inhibitors for Cancer Treatment.

Sun Y, Chen M, Han Y, Li W, Ma X, Shi Z, Zhou Y, Xu L, Yu L, Wang Y, Yu J, Diao X, Meng L, Xu S. Sun Y, et al. Among authors: meng l. J Med Chem. 2024 Mar 14;67(5):3986-4006. doi: 10.1021/acs.jmedchem.3c02288. Epub 2024 Feb 22. J Med Chem. 2024. PMID: 38387074

2

Discovery of 7H-Pyrrolo[2,3-d]pyrimidine Derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors.

Wu F, Li H, An Q, Sun Y, Yu J, Cao W, Sun P, Diao X, Meng L, Xu S. Wu F, et al. Among authors: meng l. Eur J Med Chem. 2023 Jun 5;254:115355. doi: 10.1016/j.ejmech.2023.115355. Epub 2023 Apr 10. Eur J Med Chem. 2023. PMID: 37062169

3

Second messenger 2'3'-cyclic GMP-AMP (2'3'-cGAMP): the cell autonomous and non-autonomous roles in cancer progression.

Ma XY, Chen MM, Meng LH. Ma XY, et al. Acta Pharmacol Sin. 2024 May;45(5):890-899. doi: 10.1038/s41401-023-01210-7. Epub 2024 Jan 4. Acta Pharmacol Sin. 2024. PMID: 38177693 Review.

4

The double faced role of xanthine oxidoreductase in cancer.

Chen MM, Meng LH. Chen MM, et al. Acta Pharmacol Sin. 2022 Jul;43(7):1623-1632. doi: 10.1038/s41401-021-00800-7. Epub 2021 Nov 22. Acta Pharmacol Sin. 2022. PMID: 34811515 Free PMC article. Review.

5

Xanthine dehydrogenase rewires metabolism and the survival of nutrient deprived lung adenocarcinoma cells by facilitating UPR and autophagic degradation.

Chen MM, Guo W, Chen SM, Guo XZ, Xu L, Ma XY, Wang YX, Xie C, Meng LH. Chen MM, et al. Among authors: meng lh. Int J Biol Sci. 2023 Jan 1;19(3):772-788. doi: 10.7150/ijbs.78948. eCollection 2023. Int J Biol Sci. 2023. PMID: 36778128 Free PMC article.

6

Design, synthesis, and biological activity evaluation of (-)-6-O-desmethylantofine analogues as potent anti-cancer agents.

Han G, Qing L, Wu M, Wang Y, Liu Y, Liu X, Wang Z, Ding J, Meng LH, Wang Q. Han G, et al. Among authors: meng lh. Bioorg Med Chem. 2019 Jul 15;27(14):3070-3081. doi: 10.1016/j.bmc.2019.05.030. Epub 2019 May 21. Bioorg Med Chem. 2019. PMID: 31171403

7

Comparative genomic analysis of esophageal squamous cell carcinoma and adenocarcinoma: New opportunities towards molecularly targeted therapy.

Zhang X, Wang Y, Meng L. Zhang X, et al. Among authors: meng l. Acta Pharm Sin B. 2022 Mar;12(3):1054-1067. doi: 10.1016/j.apsb.2021.09.028. Epub 2021 Sep 30. Acta Pharm Sin B. 2022. PMID: 35530133 Free PMC article. Review.

8

Targeting PI3Kα overcomes resistance to KRas^G12C inhibitors mediated by activation of EGFR and/or IGF1R.

Qi WL, Li HY, Wang Y, Xu L, Deng JT, Zhang X, Wang YX, Meng LH. Qi WL, et al. Among authors: meng lh. Acta Pharmacol Sin. 2023 May;44(5):1083-1094. doi: 10.1038/s41401-022-01015-0. Epub 2022 Nov 21. Acta Pharmacol Sin. 2023. PMID: 36411339 Free PMC article.

9

Covalent inhibitor targets KRas^G12C: A new paradigm for drugging the undruggable and challenges ahead.

Li HY, Qi WL, Wang YX, Meng LH. Li HY, et al. Genes Dis. 2021 Sep 28;10(2):403-414. doi: 10.1016/j.gendis.2021.08.011. eCollection 2023 Mar. Genes Dis. 2021. PMID: 37223497 Free PMC article. Review.

10

Repressing MYC by targeting BET synergizes with selective inhibition of PI3Kα against B cell lymphoma.

Chen ZQ, Cao ZR, Wang Y, Zhang X, Xu L, Wang YX, Chen Y, Yang CH, Ding J, Meng LH. Chen ZQ, et al. Among authors: meng lh. Cancer Lett. 2022 Jan 1;524:206-218. doi: 10.1016/j.canlet.2021.10.022. Epub 2021 Oct 22. Cancer Lett. 2022. PMID: 34688842

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

7,286 results

Search Page

Filters